toxylact: a05ba04 citiolone

The first professional lActological database in the word

Citiolone (ATC A05BA04) is a hepatoprotective and antioxidant agent used in liver therapy, classified within the ATC group A05BA “Liver therapy.”medpedia.framar+1

ATC class and general characteristics

Citiolone belongs to the ATC class A05BA04, which includes liver therapy agents used for supportive treatment of hepatic diseases.atcddd.fhi
Chemically, citiolone is N‑acetylhomocysteine thiolactone, a derivative of the sulfur‑containing amino acid homocysteine and related to cysteine biology.wikipedia+2
It is considered an antioxidant and hepatoprotective drug, intended as adjunctive therapy in acute and chronic liver diseases and toxic liver injury.drugs.ncats+2

Mechanism of action and pharmacology

Citiolone acts primarily as an antioxidant and free‑radical scavenger, reducing oxidative stress in hepatocytes and other tissues.chemicalbook+1
As an N‑acetylhomocysteine thiolactone, it serves as a source of thiol groups and can enhance cellular cysteine availability, indirectly supporting glutathione synthesis and detoxification pathways.pubmed.ncbi.nlm.nih+1
This antioxidant effect is associated with protection against reactive oxygen species and has been linked to hepatoprotective and potential neuroprotective properties in experimental models.drugs.ncats+1

Therapeutic uses

Citiolone is used in liver therapy for conditions such as acute hepatitis, chronic hepatitis, toxic liver damage, and other hepatic dysfunctions, often as part of combination products.kegg+2
Clinical use includes indications like infections and toxic liver diseases, sequelae of chronic hepatitis, and supportive treatment after exposure to hepatotoxic agents or irradiation.medpedia.framar+2
It has also been studied for other potential applications, including hypothermia and mucolytic or muco‑regulating effects, although these are secondary to its established hepatoprotective role.wikipedia+1

Dosage and administration (non‑lactation specific)

Commercial preparations may contain citiolone alone or in fixed combinations, for example tablets with citiolone and L‑cysteine used multiple times daily with meals.drugs.ncats
Therapeutic regimens are typically short to medium term and tailored according to the underlying hepatic condition, severity of disease, and concomitant medications.chemicalbook+1
Because formulations and authorised indications vary by jurisdiction, dosing must follow local product information and specialist guidance.

Adverse effects and contraindications

Reported adverse effects of citiolone are relatively infrequent but may include gastrointestinal disturbances, allergic reactions and, rarely, idiosyncratic intolerance, consistent with its thiol‑containing structure.chemicalbook+1
The Bulgarian source notes hypersensitivity to the medicinal product or its components as a contraindication, in line with general practice for hepatoprotective agents.medpedia.framar
Caution is recommended in patients with a history of sulfur‑containing amino acid intolerance, severe hepatic failure, or in those receiving multiple hepatotoxic drugs, and monitoring of liver function is advised.chemicalbook+1

Toxicological profile

From a toxicological perspective, citiolone is considered of low acute toxicity at therapeutic doses, but comprehensive human toxicity data remain limited.drugs.ncats+1
Preclinical data suggest antioxidant and cytoprotective activity rather than direct cytotoxicity; nonetheless, overdoses or use in patients with advanced hepatic failure may theoretically worsen metabolic imbalance and should be avoided.pubmed.ncbi.nlm.nih+1
Long‑term safety data, carcinogenicity and reproductive toxicity studies are sparse, so prudent avoidance of unnecessary prolonged high‑dose exposure is advisable.

Lactation safety and risk assessment

Specific, well‑characterised human data on citiolone during breastfeeding are lacking, and it is not included in the major lactation safety summaries available online.kellymom
Given its small molecular size and water solubility, passage into breast milk is biologically plausible, but the extent and clinical significance of infant exposure are unknown.pubmed.ncbi.nlm.nih+1
In the absence of robust data, citiolone should be approached as a medication with unknown lactation risk: use only when the maternal benefit in significant liver disease outweighs the theoretical risk to the breastfed infant, with close clinical monitoring.

Practical lactological considerations

When assessing citiolone for a breastfeeding patient, clinicians should consider the severity of the maternal hepatic condition, availability of alternative hepatoprotective therapies with better‑defined lactation profiles (e.g. silymarin), and the age and health of the infant.atcddd.fhi+1
Short‑term use at the lowest effective dose, preferably in full‑term, healthy infants, is likely to carry a lower theoretical risk than long‑term or high‑dose therapy, but this remains extrapolated rather than evidence‑based.kellymom+1
If citiolone is used, infant monitoring for feeding difficulties, gastrointestinal symptoms, rash or unusual behaviour is prudent, and any concerns should prompt paediatric evaluation and reconsideration of therapy.kellymom

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.